Novartis AG (NVS)
- Previous Close
113.77 - Open
115.14 - Bid 115.10 x 1000
- Ask 115.13 x 1100
- Day's Range
114.97 - 115.40 - 52 Week Range
92.19 - 120.92 - Volume
199,779 - Avg. Volume
1,161,317 - Market Cap (intraday)
234.084B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
23.56 - EPS (TTM)
4.89 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield 3.78 (3.32%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
117.90
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVS
View MorePerformance Overview: NVS
Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVS
View MoreValuation Measures
Market Cap
230.04B
Enterprise Value
250.59B
Trailing P/E
23.27
Forward P/E
14.01
PEG Ratio (5yr expected)
1.73
Price/Sales (ttm)
4.80
Price/Book (mrq)
5.52
Enterprise Value/Revenue
5.13
Enterprise Value/EBITDA
13.20
Financial Highlights
Profitability and Income Statement
Profit Margin
33.11%
Return on Assets (ttm)
8.86%
Return on Equity (ttm)
21.50%
Revenue (ttm)
48.86B
Net Income Avi to Common (ttm)
10.08B
Diluted EPS (ttm)
4.89
Balance Sheet and Cash Flow
Total Cash (mrq)
8.43B
Total Debt/Equity (mrq)
69.18%
Levered Free Cash Flow (ttm)
14.81B